MitoQ for Fatigue in Multiple Sclerosis (MS)

Summary

The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.

Timeline

Start

2020-04-01

Primary completion

2024-10-15

Completion

2026-03-31

Drugs

Indications